SMMT — Summit Therapeutics Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.57bn
U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte Software
U.S. STOCKS ON THE MOVE-Meta, Chime Financial, ServiceTitan
Jefferies upgrades Summit Therapeutics to "buy", shares up
Brief: Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Pembrolizumab Monotherapy In Pd-L1-Positive Advanced Nsclc In Harmoni-2 Study Conducted By Akeso In China
Brief: Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer In Single-Region Trial Conducted By Akeso In China
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Summit gains after partner Akeso secures China nod for lung cancer combo
Brief: Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor
U.S. STOCKS ON THE MOVE-Tenet Healthcare, Intel, Verizon
U.S. STOCKS ON THE MOVE-Tenet Healthcare, Intel, Verizon
Summit Therapeutics falls after share sale plans, Q2 report
Brief: Summit Therapeutics To Offer And Sell Common Stock Up To $380 Million Aggregate Through Sales Agent - SEC Filing
Summit Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Summit Therapeutics Q2 net loss narrows on lower stock compensation
Brief: Summit Therapeutics Q2 Net Income USD -215.7 Million
Brief: Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration